Service brochures.
Lead development of single-domain antibodies Production & purification
- sdAbs derived from camelid antibodies
- QVQ services for developing sdAb panels
- Optional follow-up services
- QVQ services for production and purification
Functionalizations of single-domain antibodies – Conjugation Services & Reagents
- Directional conjugation of sdAbs
- QVQ services for sdAb conjugations
- Applications of sdAbs in fluorescent technologies and advanced imaging
Application Note.
Directional conjugation of single-domain antibodies enables their application in fluorescence technologies and advanced imaging
This application note highlights the advantages of fluorescent single-domain antibodies in fluorescence-based technologies and advanced imaging.
Due to their small size, labeled sdAbs have a small linkage error leading to robust signals and improved resolution. They are also cleared quickly from the bloodstream and have enhanced tissue penetration leading to good signal-to-noise ratios.
Frequently asked questions.
What are the deliverables of a standard lead development project?
A lead development project at QVQ is always custom-made to meet the needs of your project. Often included are the delivery of single-domain antibody phagemid libraries, masterplates of monoclonal antibodies, including individual sequences, and delivery of 0.2 mg purified material of 10-12 lead candidates accompanied with experimental data.
How does the “no cure, no pay” work at QVQ?
A project is divided into work packages led by a dedicated project manager. Together with the customer, it is decided whether the work package has been delivered. If not, QVQ will not invoice this work package. Thus, if no specific single-domain antibodies against the target of interest are found, the panning and selection work package will not be invoiced.
Who owns the IP of the project?
All intellectual property corresponding to the lead development project or the production, purification, and characterization of single-domain antibodies is transferred to the customer and is fully owned by the customer to allow protection and further development of the molecules.
Do you sacrifice the animals after immunization?
No, immunizations are done by accredited partners, and we only use a small volume of blood for serum titration and RNA extraction of PBMCs. Animals are routinely reused for new campaigns after a resting period and are not sacrificed for the purpose of antibody development projects.
What is the success rate of lead panel antibody delivery?
Since QVQ works with a “no cure, no pay” policy, we make the effort to get high-quality antibodies out of each project. This means that if we receive good-quality immunogens and we use two animals to avoid the occasional bad responder, the success rate is >95%.
Blogs.
Functionalized single-domain antibodies for detection, imaging, and conformational sensing of CXCR4.
Single-domain antibodies (sdAbs, also known as VHH) can be derived from heavy-chain-only antibodies from members of the camelidae family like llamas and alpacas. These sdAbs are relatively small in size, stable, and have affinities to antigens that are in a similar range as conventional antibodies. Being single-domain, globular recombinant proteins,…
Every sdAb of the (path-)way: targeting factors and complexes across the complement system.
Literature.
View our complete literature list of publications over here.